Related Experiment Video

Updated: Jun 29, 2025

Application of Hemostatic Devices in Laparoscopic Hepatectomy
04:23

Application of Hemostatic Devices in Laparoscopic Hepatectomy

Published on: April 19, 2022

2.2K

Hemostasis Using Prothrombin Complex Concentrate in Patients Undergoing Cardiac Surgery: Systematic Review with

Jun-Ping Li1, Yan Li2, Bing Li3

  • 1Medical Oncology, Zibo Municipal Hospital, Zibo, Shandong, People's Republic of China.

Brazilian Journal of Cardiovascular Surgery
|April 3, 2024
PubMed

Insights

Prothrombín complex concentrate (PCC) use in cardiac surgery did not increase mortality or hospital stay. However, PCC significantly reduced postoperative intensive care unit stay, bleeding, and the need for mechanical circulatory support.

Area of Science:

  • Cardiology
  • Anesthesiology
  • Critical Care Medicine

Background:

  • Massive bleeding is a significant complication in cardiac surgery.
  • Prothrombín complex concentrate (PCC) is used to manage bleeding, but its efficacy and safety in cardiac surgery patients require comprehensive evaluation.

Purpose of the Study:

  • To comprehensively explore the efficacy and safety of prothrombín complex concentrate (PCC) for treating massive bleeding in patients undergoing cardiac surgery.

Main Methods:

  • A meta-analysis was conducted, searching PubMed, Embase, and Cochrane Library for relevant studies published before September 10, 2022.
  • Continuous data were analyzed using mean difference (MD) with 95% confidence intervals (CI), and dichotomous data were analyzed using risk ratios (RR) with 95% CI.

Main Results:

  • Twelve studies were included. PCC was not associated with increased mortality, shorter hospital stay, reduced thoracic drainage, or higher rates of thromboembolic events, atrial fibrillation, or myocardial infarction compared to non-PCC regimens.
  • However, PCC use was linked to a reduced intensive care unit length of stay (MD=-0.81 days, P=0.02), decreased bleeding (MD=-248.67 ml, P=0.02), and a lower incidence of intra-aortic balloon pump/extracorporeal membrane oxygenation use (RR=0.65, P=0.05).

Conclusions:

  • Prothrombín complex concentrate (PCC) administration in cardiac surgery patients does not correlate with increased mortality, hospital stay, thoracic drainage, or specific adverse events like atrial fibrillation, myocardial infarction, or thromboembolic events.
  • PCC significantly improves postoperative outcomes, including reduced intensive care unit stay, decreased blood loss, and less need for mechanical circulatory support (intra-aortic balloon pump/extracorporeal membrane oxygenation).
Abstract

Keywords:
Cardiac SurgeryHemorrhageMeta-AnalysísMortalityMyocardial InfarctionProthrombin Complex ConcentrateSystematic Review

More Related Videos

Hemocompatibility Testing of Blood-Contacting Implants in a Flow Loop Model Mimicking Human Blood Flow09:41

Hemocompatibility Testing of Blood-Contacting Implants in a Flow Loop Model Mimicking Human Blood Flow

Published on: March 5, 2020

9.2K
Fully Endoscopic Mitral Valve Repair with Percutaneous Cannulation of Groin Vessels08:12

Fully Endoscopic Mitral Valve Repair with Percutaneous Cannulation of Groin Vessels

Published on: May 26, 2023

1.6K

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
690
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
7.5K
Introduction to Hemostasis01:05

Introduction to Hemostasis

Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
7.6K
Coagulation01:09

Coagulation

The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
6.5K